We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured

Journal Scan / Research · September 07, 2020

ERBB2 mRNA Expression Is Associated With Response to T-DM1 in HER2+ Breast Cancer

Cancers

 

Additional Info

Disclosure statements are available on the authors' profiles:

Cancers
ERBB2 mRNA Expression and Response to Ado-Trastuzumab Emtansine (T-DM1) in HER2-Positive Breast Cancer
Cancers (Basel) 2020 Jul 14;[EPub Ahead of Print], G Griguolo, F Brasó-Maristany, B González-Farré, T Pascual, N Chic, T Saurí, R Kates, O Gluz, D Martínez, L Paré, V Tsvetkova, D Pesantez, M Vidal, B Adamo, M Muñoz, P Galván, L Barberá, M Cuatrecasas, M Christgen, H Kreipe, I Monge-Escartín, P Villagrasa, D Soy, T Giarratano, MV Dieci, P Conte, N Harbeck, V Guarneri, A Prat

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading